{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:01:51Z","timestamp":1791918111361,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["205695"],"award-info":[{"award-number":["205695"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhepr.2026.101923","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:22:01Z","timestamp":1780986121000},"page":"101923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signaling"],"prefix":"10.1016","volume":"8","author":[{"given":"Megan E.","family":"Ermler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6506-2208","authenticated-orcid":false,"given":"Jared L.","family":"Delahaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-0853","authenticated-orcid":false,"given":"William","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Nivarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2488-4995","authenticated-orcid":false,"given":"Anne","family":"DeHart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2593-791X","authenticated-orcid":false,"given":"Kristen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-3194","authenticated-orcid":false,"given":"Nicholas","family":"Galwey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Tarrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriia","family":"Sherina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijit","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-0332","authenticated-orcid":false,"given":"Jennifer M.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickens","family":"Theodore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Paff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihyun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101923_bib1","series-title":"Global hepatitis report 2024","year":"2024"},{"key":"10.1016\/j.jhepr.2026.101923_bib2","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV\/HDV treatment endpoints conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101923_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1075916","article-title":"Hepatitis B functional cure and immune response","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib4","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101923_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003088-199528010-00002","article-title":"Pharmacokinetics of antisense oligonucleotides","volume":"28","author":"Agrawal","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhepr.2026.101923_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cpdd.670","article-title":"A randomized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects","volume":"8","author":"Han","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jhepr.2026.101923_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/v12080851","article-title":"Advances with RNAi-based therapy for hepatitis B virus infection","volume":"12","author":"van den Berg","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jhepr.2026.101923_bib8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1261\/rna.079699.123","article-title":"Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging","volume":"29","author":"Spencer-Dene","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.jhepr.2026.101923_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000489966","article-title":"Characterization of pattern recognition receptor expression and functionality in liver primary cells and derived cell lines","volume":"10","author":"Faure-Dupuy","year":"2018","journal-title":"J Innate Immun"},{"key":"10.1016\/j.jhepr.2026.101923_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","article-title":"Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101923_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/0192623318813143","article-title":"Comparison of the class effects of antisense oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 mice","volume":"47","author":"Kim","year":"2019","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jhepr.2026.101923_bib12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1089\/nat.2017.0668","article-title":"The distinct and Cooperative roles of toll-like receptor 9 and receptor for advanced glycation end products in modulating in vivo inflammatory responses to select CpG and non-CpG oligonucleotides","volume":"27","author":"Paz","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jhepr.2026.101923_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/nat.2015.0588","article-title":"Lack of interactions between an antisense oligonucleotide with 2'-O-(2-Methoxyethyl) modifications and major drug transporters","volume":"26","author":"Yu","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jhepr.2026.101923_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12079-009-0062-6","article-title":"The role of SPARC in extracellular matrix assembly","volume":"3","author":"Bradshaw","year":"2009","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.jhepr.2026.101923_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/imr.13081","article-title":"Osteopontin\/secreted phosphoprotein-1 harnesses glial-, immune-, and neuronal cell ligand-receptor interactions to sense and regulate acute and chronic neuroinflammation","volume":"311","author":"Yim","year":"2022","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jhepr.2026.101923_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejcb.2011.01.017","article-title":"The amyloid precursor protein and its homologues: structural and functional aspects of native and pathogenic oligomerization","volume":"91","author":"Kaden","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.jhepr.2026.101923_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3851\/IMP3363","article-title":"Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects","volume":"25","author":"Reyes","year":"2020","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2026.101923_bib18","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib19","article-title":"Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib20","series-title":"DIA\/FDA oligonucleotide-based therapeutics conference","author":"Hood","year":"2024"},{"key":"10.1016\/j.jhepr.2026.101923_bib21","article-title":"Treatment with GSK3228836 leads to HBsAg reduction and induction of interferon gamma related proteins and chemokines in a Phase 2a, randomized, double-blind, placebo-controlled study","author":"You","year":"2021","journal-title":"The Int Liver Congress Virtual"},{"key":"10.1016\/j.jhepr.2026.101923_bib22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101923_bib23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib25","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3389\/fimmu.2018.01523","article-title":"Toll-like receptors, associated biological roles, and signaling networks in non-mammals","volume":"9","author":"Nie","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.molimm.2009.11.003","article-title":"A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition","volume":"47","author":"Liu","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib27","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.0c00100","article-title":"Discovery of GS-9688 (selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B","volume":"63","author":"Mackman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhepr.2026.101923_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.735913","article-title":"Follicular helper T (T(FH)) cell targeting by TLR8 signaling for improving HBsAg-specific B cell response in chronic hepatitis B patients","volume":"12","author":"Ayithan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1369\/0022155416656154","article-title":"The expression of toll-like receptors in normal human and murine gastrointestinal organs and the effect of microbiome and cancer","volume":"64","author":"Huhta","year":"2016","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jhepr.2026.101923_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic potential of TLR8 agonist GS-9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101923_bib31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","article-title":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","volume":"78","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101923_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004210","article-title":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"10","author":"Jo","year":"2014","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhepr.2026.101923_bib33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1006\/cyto.1999.0672","article-title":"TNF-alpha is a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1beta and IFN-gamma","volume":"12","author":"Narumi","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.jhepr.2026.101923_bib34","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1182\/blood.V95.12.3823.012k07_3823_3831","article-title":"LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-alpha","volume":"95","author":"Xaus","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2026.101923_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/nat.2022.0033","article-title":"Early-stage identification and avoidance of antisense oligonucleotides causing species-specific inflammatory responses in human volunteer peripheral blood mononuclear cells","volume":"32","author":"Burel","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jhepr.2026.101923_bib36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.4049\/jimmunol.1600757","article-title":"Selectivity of human TLR9 for double CpG motifs and implications for the recognition of genomic DNA","volume":"198","author":"Pohar","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib37","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMc2216469","article-title":"Efficacy and safety of bepirovirsen in hepatitis B","volume":"388","author":"Vaillant","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101923_bib38","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jhep.2022.09.002","article-title":"Bepirovirsen\/GSK3389404: antisense or TLR9 agonists?","volume":"78","author":"Vaillant","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101923_bib39","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.jhep.2022.11.023","article-title":"Reply to: \"Bepirovirsen\/GSK3389404: antisense or TLR9 agonists?\"","volume":"78","author":"You","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101923_bib40","first-page":"1147","article-title":"Efficacy and safety of bepirovirsen in hepatitis B. Reply","volume":"388","author":"Yuen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101923_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.omtn.2022.01.020","article-title":"Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection","volume":"27","author":"Ushach","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhepr.2026.101923_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bmc.2017.11.020","article-title":"TLR8 activation and inhibition by guanosine analogs in RNA: importance of functional groups and chain length","volume":"26","author":"Hu","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jhepr.2026.101923_bib43","article-title":"A single naturally occurring 2'-O-methylation converts a TLR7- and TLR8-activating RNA into a TLR8-specific ligand","volume":"10","author":"Jung","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2026.101923_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911139","article-title":"Identification of an optimal TLR8 ligand by alternating the position of 2'-O-ribose methylation","volume":"23","author":"Nicolai","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2026.101923_bib45","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1261\/rna.061952.117","article-title":"Identification of an optimized 2'-O-methylated trinucleotide RNA motif inhibiting Toll-like receptors 7 and 8","volume":"23","author":"Schmitt","year":"2017","journal-title":"RNA"},{"key":"10.1016\/j.jhepr.2026.101923_bib46","first-page":"7052","article-title":"Rational design of antisense oligonucleotides modulating the activity of TLR7\/8 agonists","volume":"48","author":"Alharbi","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhepr.2026.101923_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-022-00436-7","article-title":"Targeting toll-like receptor 7\/8 for immunotherapy: recent advances and prospectives","volume":"10","author":"Sun","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.jhepr.2026.101923_bib48","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41590-018-0068-4","article-title":"Recognition of microbial viability via TLR8 drives T(FH) cell differentiation and vaccine responses","volume":"19","author":"Ugolini","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhepr.2026.101923_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/v13091767","article-title":"Treatments for HBV: a glimpse into the future","volume":"13","author":"Bartoli","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jhepr.2026.101923_bib50","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:20:24Z","timestamp":1790112024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589555926001941"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101923","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signaling","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 GSK PLC. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101923"}}